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Neoadjuvant reatment in oesophageal cancer: 
the needs for future trials 
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In view of the poor survival after surgery alone for oesophageal cancer, combination with chemotherapy seems rational. 
A concept of upfront chemotherapy is discussed and seems especially useful for these tumours. The published randomized 
trials, studying the effect of neoadjuvant chemotherapy do, however, not (yet) show an improved overall survival, apart 
from one study with a significant median survival benefit at an interim evaluation. The responding patients have in all 
trials a far better survival than the non-responders. The numbers of patients are small and results of other ongoing and 
future trials should be awaited. New trials testing high-dose chemotherapy with bone marrow support should be initiated. 
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The outlook for patients with oesophageal cancer is poor. 
Although peri-operative mortality has decreased 
substantially in the past decades, the 5-year survival rate is 
still about 10% or less in those patients with loco-regional 
disease who have been operated upon with curative intent.~'2 
Micrometastatic dissemination resulting in a high proportion 
of regional and distant failures are common events, especially 
in Western patients, who may present late, and frequently 
have T3_4,N + tumours. 3-6 The situation in Asia, China and 
Japan is different, as this tumour type is among the most 
frequently observed malignancies, and where screening 
programmes have certainly resulted in a high proportion of 
stage I patients, with good results after loco-regional 
treatment alone. This aside, it appears justified to consider a
patient with locooregional cancer of the oesophagus a having 
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advanced isease at the time ofdiagnosis. The use of systemic 
treatment incombination with local modalities ( urgery and/ 
or radiotherapy) seems rational. 
Because of the relative rarity of this disease and the severe 
morbidity in many patients at the time of diagnosis, tumours 
of the oesophagus have not been systematically tested against 
a variety of cytostatic drugs. However, both squamous cell 
carcinoma nd adenocarcinoma are chemotherapy-sensitive, 
with response rates of approximately 40-50% (somewhat 
less for adenocarcinomas) for various cisplatin-based 
combination regimens. 7 
What is the impact of timing of systemic therapy on 
the outcome? Should conventional post-operative adjuvant 
treatment be applied, as in node-positive breast cancer, or 
is there a rationale for pre-operative or neoadjuvant systemic 
treatment? Post-operative systemic chemotherapy after 
primary local treatment for oesophageal cancer has not 
been successful. After an oesophagectomy, whether by 
thoracotomy or by a transhiatal approach, many patients 
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cannot be treated with systemic chemotherapy for a 
considerable time. It is impossible therefore to comply with 
the basic rule of adjuvant chemotherapy, that is to start 
systemic treatment as quick as possible? No randomized 
trials have been reported. 
The concept of neoadjuvant chemotherapy has been 
developed to induce early tumour egression, with improved 
local control when followed by subsequent surgery and/or 
radiotherapy, and an ability to identify responding and non- 
responding patients. 9'~° In addition, several animal studies 
have shown an increase in the labelling index of metastases 
after resection of the primary tumour, and a better survival 
when chemotherapy was given before resection. "-t4 Lastly, 
chemotherapy is likely to have a greater impact when given 
early in the course of the disease, when subclinical metastatic 
burden is low and the patient is best able to tolerate toxic 
side-effects. 
Potential drawbacks of neoadjuvant c.hemotherapy 
include: the (theoretical) possibilities of delay in achieving 
local control; a risk of tumour spread from the primary site 
in case of a chemoresistant tumour; and the creation of an 
'unnatural' tumour area with necrosis and fibrosis at the 
time of surgery in cases of chemosensitive cancers. 
Several phase II trials have been published on pre- 
operative chemotherapy in oesophageal cancer, especially 
in locally advanced isease? 5 
Major responses with cisplatin-based combination 
chemotherapy have been documented in 15 to 70% with 
complete pathological responses in 4 to 10%o f patients. 
Operative mortality seems to be comparable to surgery 
alone. The combination of cisplatin on day 1 and 5- 
fluorouracil on days 1-4 has been studied extensively, and 
has become a standard, against which new combinations 
are being compared. ~6-t9 Although pre-operative systemic 
treatment seems to be safe, and operability, resectability 
and post-operative mortality are comparable with surgery 
alone, no clear survival benefit has been demonstrated in 
the above-mentioned phase II trials, which, by their nature, 
are not appropriate for testing survival differences. 
Until now, three prospective randomized trials have been 
published, comparing neoadjuvant chemotherapy followed 
by surgery vs surgery alone. Roth et al. treated 17 patients 
with epidermoid carcinoma after randomization with 2 
cycles of cisplatin, vindesine and bleomycine before surgery, 
followed by a 6-month period of post-operative 
chemotherapy with cisplatin and vindesine. 2° Although 
patients responding to chemotherapy had a significantly 
prolonged survival (median: >20 months), overall survival 
was no different for surgery alone or neoadjuvant 
chemotherapy with surgery. Resectability and post- 
operative complication rate were similar. Schlag et al. 
reported in 1992 the results of a randomized phase III 
study, in which the duration of pre-operative treatment was 
dependent on a response valuation after only 1 cycle with 
cisplatin and 5-fluorouracil; patients with no change or 
progression were operated upon at once, while responding 
patients were treated with another 2 cycles. 2t The response 
rate was 47°,4. Chemotherapy was associated with more 
post-operative complications, like sepsis and respiratory 
problems, and overall survival was not influenced by 
neoadjuvant treatment (median 10 months), but, as in the 
study by Roth, responding patients had a prolonged survival 
(median: 13 months) when compared with non-responders 
(median: 5 months). 
A 4-arm study was reported in 1992 by Nygaard et al., 
who randomized patients between surgery alone (n = 4 l), pre- 
operative chemotherapy with cisplatin and bleomycin (n = 
50), pre-operative radiotherapy (n=48), or pre-operative 
chemoradiotherapy (n =47). :2 No data concerning response 
evaluation after chemotherapy or chemo- 
radiotherapy are available. Patients with pre-operative 
treatment had no survival benefit compared with 'surgery 
alone. Two prospective randomized trials were reported very 
recently in abstract form. Fok et al. 23 from Hong Kong 
presented results of a prospective randomized study on pre- 
operative chemotherapy (2 cycles of cisplatin and 5- 
fluorouracil) vs surgery alone. One hundred and sixty patients 
were randomized. There was a high resectability rate in both 
groups (88% vs 93%), and a high response rate after 
chemotherapy, with 19% complete responses and 32%o partial 
responses. Median survival was the same for both groups: 12 
months. The 5-year survival rate for responding patients was 
52%, for non-responders 10%, and for the control group I 1%. 
Kok et al. 24 presented results ofan interim analysis of a similar 
study in which the duration of pre-operative chemotherapy 
was dependent on the response valuation after 2 cycles of 
chemotherapy with cisplatin and etoposide; in case of a clear 
response, another 2cycles were given pre-operatively, and in 
case of no response, the patient was operated on at once. In 
this ongoing trial, approximately I00 patients were 
randomized. With a median follow-up of 17.5 months there 
was a statistically significant median survival benefit after 
chemotherapy, not only for responding patients but also for 
the chemotherapy group as a whole. Final results with a 
longer follow-up are needed to draw definitive conclusions. 
Two large scale phase III trials are now underway: the 
US Intergroup trial (Nr 0113) randomizing more than 400 
patients with squamous cell carcinoma nd adenocarcinoma 
to receive 3 neoadjuvant and 2 post-operative chemotherapy 
cycles with cisplatin and 5-fluorouracil vs surgery alone. 
This trial has recently stopped patient entry, and results are 
awaited. An ongoing European trial (the MRC trial from 
the UK) is investigating the effect of 2 cycles of 
chemotherapy with cisplatin and 5-fluorouracil followed by 
surgery vs surgery alone in patients with squamous- or 
adenocarcinoma. No definitive results from this trial will 
be available in the short-term. 
Several phase II trials have discussed the value of 
neoadjuvant chemotherapy with concurrent radiotherapy, 
followed by resection. The rationale behind this may be the 
chance to eradicate a greater proportion of cells, including 
resistant subpop.ulations, from the start of treatment. 25 Also 
a smaller tumour mass may be more sensitive to radiation 
because of better central oxygenation. 
A non-randomized phase II study by the SWOG and 
RTOG in the US, treating more than 150 patients pre- 
operatively with cisplatin and 5-fluorouracil plus 30 Gy of 
concurrent radiotherapy, resulted in a median survival of 12 
months, which is no different from those found with surgery 
alone. 26 A randomized French study published in 1994, using 
2 short cycles of cisplatin and 5-fluorouracil, interspersed 
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with 20 Gy of radiation followed by resection, showed no 
survival benefit in the experimental group of patients. -'7 
Better results have been achieved with systemic 
chemotherapy and concurrent radiotherapy than with 
radiotherapy alone. Important data from such a randomized 
trial have been published by Herskovic et al. in 1992. -,8 
The trial was stopped after the accumulated results in 121 
patients demonstrated a significant advantage for survival 
in patients who received chemotherapy and concurrent 
radiotherapy. No long-term survival data have been 
published yet. 
What can we learn from the data available so far? Surgery 
alone seems to remain the standard of care for surgically 
treatable patients. The completion of the above-mentioned 
phase III randomized trials need to be available before 
a definitive place for neoadjuvant chemotherapy can be 
established. In several trials a survival benefit has been 
shown for those patients manifesting a major objective 
response to neoadjuvant chemotherapy. Although a 
response to chemotherapy may not be a totally independent 
prognostic factor, an intensification of the known 
chemotherapy schedules with bone marrow support by 
colony stimulating factors, and the implementation of new 
active compounds, with the aim of increasing the response 
rate (especially complete responses), should be issues for 
forthcoming research. -'~'3~ In the meantime the discovery of 
new tools to differentiate between responding and non- 
responding patients as early as possible in the period of 
pre-operative treatment, perhaps even before the start of 
treatment, should be pursued. If, eventually, neoadjuvant 
treatment should result in a better survival after surgery, 
then a randomized study, evaluating the best local treatment: 
surgery vs radiotherapy, should be initiated, including 
quality of life measurements. 
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